Hansen Health Industry Co., Ltd. announced that it expects to receive CNY 138 million in funding from Hunan Hansen Pharmaceutical Co., Ltd.
January 13, 2021
Share
Hansen Health Industry (Hunan) Co., Ltd. announced that it will receive CNY 138 million in an equity round of funding on January 14, 2021. The transaction will include participation from returning investor Hunan Hansen Pharmaceutical Co., Ltd. (SZSE:002412) and will retain its 100% stake in the company. Post the closing of the transaction, the registered capital of the company will increase from CNY 62 million to CNY 200 million. The transaction has been approved by investor's in president’s office, and there is no need of approval of board of directors and shareholders meeting.
Hunan Hansen Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, manufacture and sales of traditional Chinese medicine preparations, chemical medicine and medical preparations. The Companyâs main products include Simotang oral liquid, used for abdominal distention and phlegmatic abdominalgia; Yushangling capsules, used for injuries from falls; Yinxingye capsules, used for stroke and chest distress, as well as Suoquan capsules, used for kidney deficiency, among others. The Company mainly distributes its products in domestic markets.
HUNAN HANSEN PHARMACEUTICAL CO., LTD. 
